Altered caspase function can also be a consequence of modified expression of their specific inhibitors, as an example cFLIPs that competes with caspase 8 for FADD binding, thus preventing its activation, is often elevated in tumours, while its down-regulation can sensitize tumour cells to therapy. This evidence concerns the gene CASP8 and neoplasm.